During the last session, Replimune Group Inc (NASDAQ:REPL)’s traded shares were 2.4 million, with the beta value of the company hitting 0.61. At the end of the trading day, the stock’s price was $9.37, reflecting an intraday gain of 11.15% or $0.94. The 52-week high for the REPL share is $17.00, that puts it down -81.43 from that peak though still a striking 47.49% gain since the share price plummeted to a 52-week low of $4.92. The company’s market capitalization is $722.30M, and the average intraday trading volume over the past 10 days was 1.72 million shares, and the average trade volume was 1.03 million shares over the past three months.
Replimune Group Inc (REPL) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.14. REPL has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.84.
Replimune Group Inc (NASDAQ:REPL) trade information
Replimune Group Inc (REPL) registered a 11.15% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 11.15% in intraday trading to $9.37, hitting a weekly high. The stock’s 5-day price performance is 10.76%, and it has moved by -0.21% in 30 days. Based on these gigs, the overall price performance for the year is 79.50%. The short interest in Replimune Group Inc (NASDAQ:REPL) is 9.22 million shares and it means that shorts have 8.64 day(s) to cover.
The consensus price target of analysts on Wall Street is $23, which implies an increase of 59.26% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $19 and $27 respectively. As a result, REPL is trading at a discount of -188.15% off the target high and -102.77% off the low.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.98M as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 8.69M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -14.85%. While earnings are projected to return 5.40% in 2025, the next five years will return 22.36% per annum.
REPL Dividends
Replimune Group Inc is due to release its next quarterly earnings on 2025-May-21. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Replimune Group Inc (NASDAQ:REPL)’s Major holders
Replimune Group Inc insiders own 4.51% of total outstanding shares while institutional holders control 107.31%, with the float percentage being 112.38%. BAKER BROS. ADVISORS LP is the largest shareholder of the company, while 228.0 institutions own stock in it. As of 2024-06-30, the company held over 10.05 million shares (or 14.5193% of all shares), a total value of $90.41 million in shares.
The next largest institutional holding, with 9.24 million shares, is of PRICE T ROWE ASSOCIATES INC /MD/’s that is approximately 13.3496% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $83.13 million.
Also, the Mutual Funds coming in first place with the largest holdings of Replimune Group Inc (REPL) shares are T. Rowe Price New Horizons Fund, Inc. and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund. Data provided on Dec 31, 2024 indicates that T. Rowe Price New Horizons Fund, Inc. owns about 4.73 shares. This amounts to just over 6.14 percent of the company’s overall shares, with a $44.32 million market value. The same data shows that the other fund manager holds slightly less at 1.99, or about 2.58% of the stock, which is worth about $18.63 million.
